Inhibition of the autocrine IL-6–JAK2–STAT3–calprotectin axis as targeted therapy for HR−/HER2+ breast cancers

Genes and Development

Volumn 29, Issue 15, 2015, Pages 1631-1648

  Rodriguez Barrueco, Ruth ^a   Yu, Jiyang ^b   Saucedo Cuevas, Laura P ^a   Olivan, Mireia ^a   Llobet Navas, David ^a   Putcha, Preeti ^b   Castro, Veronica ^b   Murga Penas, Eva M ^b   Collazo Lorduy, Ana ^a   Castillo Martin, Mireia ^a   Alvarez, Mariano ^b   Cordon Cardo, Carlos ^a   Kalinsky, Kevin ^c   Maurer, Matthew ^b,c   Califano, Andrea ^b,d   Silva, Jose M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c NewYork Presbyterian Hospital   (United States)

^d Department of Biomedical Informatics ^*  (United States)

Author keywords

Breast cancer; Genetic screen; HER2; STAT3; Tailored therapies

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CALGRANULIN; CALGRANULIN A; CALGRANULIN B; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; INTERLEUKIN 6; JANUS KINASE 2; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; QUINOLINE DERIVATIVE; TASQUINIMOD; TOCILIZUMAB;

ARTICLE; AUTOCRINE EFFECT; BREAST CANCER; CANCER INHIBITION; CARCINOGENICITY; CELL PROLIFERATION; CELLULAR SECRETION; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; GENE REGULATORY NETWORK; GENE SILENCING; GENETIC ASSOCIATION; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SECRETION; ANIMAL; BREAST NEOPLASMS; CARCINOGENESIS; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOUSE; PATHOPHYSIOLOGY; RNA INTERFERENCE; SCID MOUSE; SECRETION (PROCESS); TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOGENESIS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; HETEROGRAFTS; HUMANS; INTERLEUKIN-6; JANUS KINASE 2; MICE; MICE, SCID; QUINOLINES; RNA INTERFERENCE; STAT3 TRANSCRIPTION FACTOR;

EID: 84938899221     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.262642.115     Document Type: Article

References (68)

1. Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N, Seshan VE, et al. 2012. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150: 165–178
2. Arai K, Takano S, Teratani T, Ito Y, Yamada T, Nozawa R. 2008. S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. Curr Cancer Drug Targets 8: 243–252
3. Aytes A, Mitrofanova A, Lefebvre C, Alvarez MJ, Castillo-Martin M, Zheng T, Eastham JA, Gopalan A, Pienta KJ, Shen MM, et al. 2014. Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell 25: 638–651
4. Barbieri I, Pensa S, Pannellini T, Quaglino E, Maritano D, Demaria M, Voster A, Turkson J, Cavallo F, Watson CJ, et al. 2010a. Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. Cancer Res 70: 2558–2567
5. Barbieri I, Quaglino E, Maritano D, Pannellini T, Riera L, Cavallo F, Forni G, Musiani P, Chiarle R, Poli V. 2010b. Stat3 is required for anchorage-independent growth and metastasis but not for mammary tumor development downstream of the ErbB-2 oncogene. Mol Carcinog 49: 114–120
6. Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R, Califano A. 2005. Reverse engineering of regulatory networks in human B cells. Nat Genet 37: 382–390
7. Berclaz G, Altermatt HJ, Rohrbach V, Siragusa A, Dreher E, Smith PD. 2001. EGFR dependent expression of STAT3 (but not STAT1) in breast cancer. Int J Oncol 19: 1155–1160
8. Berishaj M, Gao SP, Ahmed S, Leslie K, Al-Ahmadie H, Gerald WL, Bornmann W, Bromberg JF. 2007. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res 9: R32
9. Bertos NR, Park M. 2011. Breast cancer—one term, many entities? J Clin Invest 121: 3789–3796
10. The Cancer Genome Atlas Network. 2012. Comprehensive molecular portraits of human breast tumours. Nature 490: 61–70
11. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, Sulman EP, Anne SL, Doetsch F, Colman H, et al. 2010. The transcriptional network for mesenchymal transformation of brain tumours. Nature 463: 318–325
12. Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, Daly L, Wels J, Theilen T, Granitto S, Zhang X, et al. 2013. The IL- 6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia 15: 848–862
13. Chung SS, Giehl N, Wu Y, Vadgama JV. 2014. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial– mesenchymal transition and cancer stem cell traits. Int J Oncol 44: 403–411
14. Citri A, Yarden Y. 2006. EGF–ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7: 505–516
15. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al. 2012. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486: 346–352
16. Dalrymple SL, Becker RE, Isaacs JT. 2007. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts. Prostate 67: 790–797
17. Dalrymple SL, Becker RE, Zhou H, DeWeese TL, Isaacs JT. 2012. Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts. Prostate 72: 638–648
18. Darnell JE. 2005. Validating Stat3 in cancer therapy. Nat Med 11: 595–596
19. Debnath J, Mills KR, Collins NL, Reginato MJ, Muthuswamy SK, Brugge JS. 2002. The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 111: 29–40
20. Debnath J, Muthuswamy SK, Brugge JS. 2003. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30: 256–268
21. Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J. 2009. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 86: 557–566
22. Fruman DA, Rommel C. 2014. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 13: 140–156
23. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, et al. 2001. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20: 2499–2513
24. Gebhardt C, Nemeth J, Angel P, Hess J. 2006. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 72: 1622–1631
25. Grebhardt S, Muller-Decker K, Bestvater F, Hershfinkel M, Mayer D. 2014. Impact of S100A8/A9 expression on prostate cancer progression in vitro and in vivo. J Cell Physiol 229: 661–671
26. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES. 2009. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138: 645–659
27. Hartman ZC, Yang XY, Glass O, Lei G, Osada T, Dave SS, Morse MA, Clay TM, Lyerly HK. 2011. HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis. Cancer Res 71: 4380–4391
28. Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, et al. 2012. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci 109: 2724–2729
29. Hermani A, De Servi B, Medunjanin S, Tessier PA, Mayer D. 2006. S100A8 and S100A9 activate MAP kinase and NF-κB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp Cell Res 312: 184–197
30. Hibino T, Sakaguchi M, Miyamoto S, Yamamoto M, Motoyama A, Hosoi J, Shimokata T, Ito T, Tsuboi R, Huh NH. 2013. S100A9 is a novel ligand of EMMPRIN that promotes melanoma metastasis. Cancer Res 73: 172–183
31. Hurley J, Doliny P, Reis I, Silva O, Gomez-Fernandez C, Velez P, Pauletti G, Powell JE, Pegram MD, Slamon DJ. 2006. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 24: 1831–1838
32. Hynes NE, Lane HA. 2005. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341–354
33. Ichikawa M, Williams R, Wang L, Vogl T, Srikrishna G. 2011. S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res 9: 133–148
34. Kallberg E, Vogl T, Liberg D, Olsson A, Bjork P, Wikstrom P, Bergh A, Roth J, Ivars F, Leanderson T. 2012. S100A9 interaction with TLR4 promotes tumor growth. PLoS One 7: e34207
35. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, et al. 2009. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27: 5529–5537
36. Kawai H, Minamiya Y, Takahashi N. 2011. Prognostic impact of S100A9 overexpression in non-small cell lung cancer. Tumour Biol 32: 641–646
37. Lefebvre C, Rajbhandari P, Alvarez MJ, Bandaru P, Lim WK, Sato M, Wang K, Sumazin P, Kustagi M, Bisikirska BC, et al. 2010. A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers. Mol Syst Biol 6: 377
38. Lemmon MA, Schlessinger J. 2010. Cell signaling by receptor tyrosine kinases. Cell 141: 1117–1134
39. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blattler WA, Lambert JM, Chari RV, Lutz RJ, et al. 2008. Targeting HER2-positive breast cancer with trastuzumab- DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68: 9280–9290
40. Luo B, Cheung HW, Subramanian A, Sharifnia T, Okamoto M, Yang X, Hinkle G, Boehm JS, Beroukhim R, Weir BA, et al. 2008. Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci 105: 20380–20385
41. Marcotte R, Brown KR, Suarez F, Sayad A, Karamboulas K, Krzyzanowski PM, Sircoulomb F, Medrano M, Fedyshyn Y, Koh JL, et al. 2012. Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov 2: 172–189
42. Margolin AA, Nemenman I, Basso K, Wiggins C, Stolovitzky G, Dalla Favera R, Califano A. 2006. ARACNe: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinformatics 7: S7
43. Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R, et al. 2011. The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24− stem cell-like breast cancer cells in human tumors. J Clin Invest 121: 2723–2735
44. Mascarenhas J, Hoffman R. 2012. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res 18: 3008–3014
45. Mesa RA, Yasothan U, Kirkpatrick P. 2012. Ruxolitinib. Nat Rev Drug Discov 11: 103–104
46. Moasser MM. 2007. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26: 6469–6487
47. Murray PJ. 2007. The JAK–STAT signaling pathway: input and output integration. J Immunol 178: 2623–2629
48. Navarro-Millan I, Singh JA, Curtis JR. 2012. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther 34: 788–802
49. Paluch-Shimon S, Ben-Baruch N, Wolf I, Zach L, Kopolovic J, Kruglikova A, Modiano T, Yosepovich A, Catane R, Kaufman B. 2009. Hormone receptor expression is associated with a unique pattern of metastatic spread and increased survival among HER2-overexpressing breast cancer patients. Am J Clin Oncol 32: 504–508
50. Patel AM, Moreland LW. 2010. Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. Drug Des Devel Ther 4: 263–278
51. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. 2000. Molecular portraits of human breast tumours. Nature 406: 747–752
52. Piovan E, Yu J, Tosello V, Herranz D, Ambesi-Impiombato A, Da Silva AC, Sanchez-Martin M, Perez-Garcia A, Rigo I, Castillo M, et al. 2013. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell 24: 766–776
53. Rawlings JS, Rosler KM, Harrison DA. 2004. The JAK/STAT signaling pathway. J Cell Sci 117: 1281–1283
54. Rodriguez-Barrueco R, Marshall N, Silva J. 2013. Pooled shRNA screenings: experimental approach. Methods Mol Biol 980: 353–370
55. Schlabach MR, Luo J, Solimini NL, Hu G, Xu Q, Li MZ, Zhao Z, Smogorzewska A, Sowa ME, Ang XL, et al. 2008. Cancer proliferation gene discovery through functional genomics. Science 319: 620–624
56. Schultz N, Marenstein DR, De Angelis DA, Wang WQ, Nelander S, Jacobsen A, Marks DS, Massague J, Sander C. 2011. Off-target effects dominate a large-scale RNAi screen for modulators of the TGF-β pathway and reveal microRNA regulation of TGFBR2. Silence 2: 3
57. Silva JM, Marran K, Parker JS, Silva J, Golding M, Schlabach MR, Elledge SJ, Hannon GJ, Chang K. 2008. Profiling essential genes in human mammary cells by multiplex RNAi screening. Science 319: 617–620
58. Sotiriou C, Pusztai L. 2009. Gene-expression signatures in breast cancer. N Engl J Med 360: 790–800
59. Soule HD, Maloney TM, Wolman SR, Peterson WD Jr, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC. 1990. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50: 6075–6086
60. Tagliabue E, Balsari A, Campiglio M, Pupa SM. 2010. HER2 as a target for breast cancer therapy. Expert Opin Biol Ther 10: 711–724
61. Testa JR, Tsichlis PN. 2005. AKT signaling in normal and malignant cells. Oncogene 24: 7391–7393
62. Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J, Nguyen M, Olsson A, Nawroth PP, Bierhaus A, et al. 2008. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 29: 2035–2043
63. Vaz-Luis I, Ottesen RA, Hughes ME, Marcom PK, Moy B, Rugo HS, Theriault RL, Wilson J, Niland JC, Weeks JC, et al. 2012. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res 14: R129
64. Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, Muthuswamy SK, Arteaga CL. 2006. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10: 25–38
65. Weerasinghe P, Garcia GE, Zhu Q, Yuan P, Feng L, Mao L, Jing N. 2007. Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides. Int J Oncol 31: 129–136
66. Wendt MK, Balanis N, Carlin CR, Schiemann WP. 2014. STAT3 and epithelial–mesenchymal transitions in carcinomas. JAKSTAT 3: e28975
67. Wormald S, Hilton DJ. 2004. Inhibitors of cytokine signal transduction. J Biol Chem 279: 821–824
68. Yu J, Putcha P, Califano A, Silva JM. 2013. Pooled shRNA screenings: computational analysis. Methods Mol Biol 980: 371–384.